Pharmacoecomonic study of oral antidiabetic drugs available in Indian pharmaceutical market

Background: Diabetes mellitus is a metabolic disorder requiring lifelong medication which further adds to comorbidity. Cost of the drug pays an important role in adherence and compliance treatment. There wide variation prices oral hypoglycemic drugs available Indian pharmaceutical market. Aims objectives study was planned evaluate cost antidiabetic various brands currently market either as single or combination. Methods: medications manufactured by companies same strength dosage form obtained from price list provided current index medical specialties December 2022-March2023. The ratio percentage for each formulation calculated analyzed. Results: Among drugs, Tab. Metformin 500 mg shows highest (809%) (9.09). fixed dose combinations, Glibenclamide 5 + 300.8% 4. Conclusions: Our that there high anti diabetics. It bring awareness about so can be reduced made affordable common man plays major patient.